Toyama Chemical Co., Ltd.
http://www.toyama-chemical.co.jp/en
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Toyama Chemical Co., Ltd.
BioNTech Ramps Up Spending To Launch 10 Pivotal Cancer Studies In 2024
As COVID-19 vaccine sales decline, the company is investing billions in a diverse oncology pipeline including antibody drug conjugates, immunotherapy and cancer vaccines
Scrip Asks...What Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering
Biotech entrepreneurs tend to be an optimistic group, and there were many pockets of hope for 2024. However, the consensus remains that depressed valuations and paucity of fresh funds will continue to pose a challenge for the sector, and companies will need to prioritize carefully and work even harder to demonstrate and create value.
BioNTech Banks On Oncology Pipeline As COVID Cash Dries Up
Like rival Moderna, company reported a steep drop in revenue, but it is still prioritizing its COVID-19 vaccine as an investment priority, while also moving ahead with multiple deals with China-based firms.
Can BioNTech Take China Early-Stage Biotech Innovation Global?
BioNTech is betting on China's innovative capabilities by inking multiple deals with local startups to expand its pipeline beyond mRNA vaccines.
Company Information
- Other Names / Subsidiaries
-
- FUJIFILM Holdings Corporation
- FUJIFILM Group
- Cellular Dynamics International, Inc.
- Opsis Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice